东阳光药正式向香港联交所提交IPO申请,计划以介绍方式在港上市,同时抛出私有化控股子公司东阳光长江药业的方案。招股书数据显示,2021-2023年及2024年上半年,东阳光药的收入分别为10.58亿元、38.14亿元、63.86亿元及25.82亿元,其中可威(磷酸奥司他韦)销售额占比分别为52.4%、81.2%、86.9%及74.9%。公司自主研发了两款用于治疗丙型肝炎的1类创新药物磷酸萘坦司...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.